BridgeBio Pharma Inc
NASDAQ:BBIO 3:59:56 PM EDT
| Market Cap (Intraday) | 8.26B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $56.15 |
| 50-Day MA | $63.67 |
| 200-Day MA | $48.68 |
BridgeBio Pharma, Inc. Stock, NASDAQ:BBIO
421 Kipling Street, Palo Alto, California 94301
United States of America
Phone: +1.650.391.9740
Number of Employees: 248
Description
BridgeBio Pharma, Inc. is a pharma company. The firm engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly and Neil Kumar on May 17, 2019 and is headquartered in Palo Alto, CA.